Published in Gene Therapy Weekly, July 28th, 2005
The cancer test will use Xpention's licensed p65 technology from the University of Texas M.D. Anderson Cancer Center. P65 is a promising marker for the early detection of malignant tumor formation and a useful tool for monitoring therapy and remission. Levels of p65 also appear to have a direct correlation to tumor mass/size.
Founded in 1904, AMC Cancer Research Center is a not-for-profit research institute dedicated to the prevention and control of cancer and other chronic diseases.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.